Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity.
Glucocorticoids are used extensively to treat autoimmune hemolytic anemias. Some beneficial effects of glucocorticoid pulse therapy have also been reported in sickle cell disease and paroxysmal nocturnal hemoglobinuria. Based on established concepts of hemoglobin (Hb) toxicity and physiologic Hb scavenger systems, we evaluated whether glucocorticoids could support an adaptive response to extracellular Hb independently of their immunosuppressive activities. Using global proteome and transcriptome analysis with mass-spectrometry (isobaric tag for relative and absolute quantitation and liquid chromatography-mass spectrometry) and gene-array experiments, we found that glucocorticoid treatment in vitro and in patients on glucocorticoid-pulse therapy polarized monocytes into a M2/alternatively activated phenotype with high Hb-scavenger receptor (CD163) expression and enhanced Hb-clearance and detoxification capability. Monocytes concurrently exposed to the interactive activity of glucocorticoids and extracellular Hb were characterized by high expression of a group of antioxidant enzymes known to be regulated by the conserved oxidative response transcription factor nuclear factor E2-related factor. Further, suppressed transferrin receptor, together with high ferroportin expression, pointed to a shift in iron homeostasis directed toward an increased cellular export of heme-derived iron. Therefore, stimulating Hb-endocytosis by CD163 and enhancing antioxidative homeostasis and iron recycling may be an essential activity of glucocorticoids that helps alleviate the adverse effects of extracellular Hb.
Vallelian
Florence
F
Internal Medicine, University Hospital, Zurich, Switzerland.
Schaer
Christian A
CA
Kaempfer
Theresa
T
Gehrig
Peter
P
Duerst
Elena
E
Schoedon
Gabriele
G
Schaer
Dominik J
DJ
D015703:Antigens, CD / Q000494:pharmacology; D015214:Antigens, Differentiation, Myelomonocytic / Q000494:pharmacology; D000975:Antioxidants; D002454:Cell Differentiation / Q000187:drug effects*; D004705:Endocytosis; D005938:Glucocorticoids / Q000494:pharmacology* / Q000627:therapeutic use; D006418:Heme / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D006706:Homeostasis; D006801:Humans; D007501:Iron / Q000378:metabolism; D009000:Monocytes / Q000166:cytology / Q000187:drug effects*; D010641:Phenotype; D011956:Receptors, Cell Surface; D000098902:CD163 Antigen
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000975:Antioxidants; D000098902:CD163 Antigen; D005938:Glucocorticoids; D006454:Hemoglobins; D011956:Receptors, Cell Surface; D006418:Heme; D007501:Iron